Humulin N (Insulin Human)

Humulin N is indicated for the long‑term management of blood glucose in adults and children with diabetes.

• Type 1 diabetes mellitus (insulin‑dependent).
• Type 2 diabetes mellitus when basal insulin is required.
• Adjunct to rapid‑acting insulin analogues for basal‑bolus regimens.
• Use during pregnancy only when benefits outweigh risks (under medical supervision).
• May be employed in patients transitioning from other intermediate‑acting insulins.
• Part of intensive insulin therapy protocols for hospitalized patients with hyperglycemia.

• Humulin N contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers the tyrosine kinase pathway, promoting translocation of GLUT‑4 transporters and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The NPH formulation releases insulin slowly, providing a basal level of activity for up to 12–18 hours after subcutaneous injection.

Adverse reactions to Humulin N may vary in frequency and severity; they are typically categorized as common or serious.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized fat accumulation or loss.
• Transient weight gain related to improved glycemic control.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Insulin antibody formation leading to unpredictable glucose response.

When prescribing or using Humulin N, clinicians and patients should consider several precautionary measures to minimize risks.

• Assess renal and hepatic function, as impairment can prolong insulin action.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Monitor blood glucose closely when initiating therapy or modifying the regimen.
• Use lower initial doses in elderly patients to reduce hypoglycemia risk.
• Avoid use in patients with known hypersensitivity to insulin human or any excipients.
• Counsel patients on proper injection technique to prevent lipohypertrophy.
• Review pregnancy status; insulin requirements may change during gestation.

Humulin N can interact with other medications that affect glucose metabolism or insulin pharmacodynamics, requiring dose adjustments or monitoring.

Avoid

• Concurrent use of other insulin products or concentrated insulin formulations without appropriate dose reduction.
• Co‑administration with sulfonylureas or meglitinides that may precipitate severe hypoglycemia.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms; monitor glucose more frequently.
• Corticosteroids and thiazide diuretics can increase insulin resistance, potentially requiring higher doses.
• Oral contraceptives or hormone replacement therapy may alter insulin requirements.